Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.50K$11.50Kderived−92.3% vs Q4 2019 Net Income-$2.03M-$2.03MderivedN/M vs Q4 2019 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$35,549N/M Operating Incomederived-$683,961N/M Operating Cash Flowderived-$192,856N/M Margins · derivedGross margin-309.1%−377.3 pt vs Q4 2019
Operating margin-5947.5%−5455.7 pt vs Q4 2019
Net margin-17654.9%−13838.9 pt vs Q4 2019
ended Dec 31, 2020 · filed Apr 13, 2021 · 103 d after period end